阿德福韦酯治疗慢性乙型肝炎疗效观察

目的:观察阿德福韦酯治疗慢性乙型肝炎的疗效。方法:34例慢性乙型肝炎患者口服阿德福韦酯,每次10 mg,每天1次,每3个月检测1次HBV DNA、肝功能及乙肝血清标志物。结果:治疗12个月时HBV DNA阴转17例,阴转率50%,其中HBV DNA<107拷贝/ml,阴转率为66.7%而HBV DNA ≥ 107拷贝/ml,阴转率为23.0%,差异有统计学意义(P=0.032);ALT<2倍正常值,阴转1/5例,而ALT>2倍正常值,阴转率为71.4%,差异无统计学意义(P=0.111),HBV DNA阴转率与乙肝血清标志物模式无明显关系(P>0.05)。结论:阿德福韦酯对低病毒载量的患者HBV DNA阴转率较高。

The clinical efficacy of adefovir on chronic hepatitis B

Objective：To observe antiviral efficacy of adefovir on chronic hepatitis B.Methods：Thirty-four cases of patients with chronic hepatitis B were administered oral dose of 10 mg of adefovir once daily.HBVDNA,hepatic function and the serum HBV markers were detected every three months.Results：After 12 months′ treatment,HBVDNA converted to negative in 17 cases（50%）.Among them,the HBVDNA negative conversion rate in patients whose HBVDNA was less than 107 cop/ml was 66.6%,and it was 23% in patients whose HBVDNA was≥10^7cop/ml.There was significant difference between these two kinds of patients（P〈0.05）.The HBVDNA negative conversion rate in patients whose ALT was less than two folds of normal value was 20%,and it was 71.4% in patients whose ALT was more than two folds of normal value.There was also significant difference between these two kinds of patients（P〈0.05）.There no correlation between HBVDNA negatives conversion rate and the mode of hepatitis B serum markers（P〉0.05）.Conclusions：Adefovir is effective in HBVDNA negative conversion rate for the patients with low HBV load and high ALT levels.